George Georgiou
Professor
Make your next move.
Prepare your application
Review drafts before you send them.
Explore related searches
Articles (27)
Protection against human norovirus infection, which is the major cause of acute gastroenteritis, is strongly correlated with humoral immunity, particularly with IgA binding titers in serum and mucosal surfaces. Serum IgA is mostly monomeric (mIgA), with 10-20% present as dimeric (dIgA). Using serum antibody proteomics, we determined the clonal composition of the serum IgG, mIgA, and dIgA repertoires specific to GII.4 virus-like particles (VLPs) following oral vaccination with an adenoviral vectored norovirus vaccine candidate, which phenocopies the route of administration and the higher IgA to IgG serum titers associated with natural infection. We detected a low level of clonal overlap between circulating IgG and IgA at steady state, which, however, increased up to 65% following vaccination. Importantly, > 80% of serum mIgA specific to VLP was also found as dIgA, yet the mIgA:dIgA abundance ratio for different clonotypes varied by up to 250-fold (0.4190). We observed a similar congruence of the influenza hemagglutinin-binding dIgA and mIgA repertoires in serum following intramuscular flu vaccination. For antibodies targeting the apex, but not the lateral cleft, of the protruding (P) domain on human norovirus VLPs, IgA dimerization conferred markedly improved ligand blockade titers, resulting in higher potency towards the neutralization of live virus in the human intestinal enteroid system. Cryo-EM structures of prototypical apical and lateral cleft binding antibodies, coupled with cryo-ET imaging of VLP cross-linking mediated by dIgA, revealed that epitope accessibility, antibody binding orientation, and proximity to the attachment ligand binding site required for virus entry into host cells all influence the epitope-dependent differential potency of dIgA. Our findings elucidate key features of the molecular nature of the IgA serological response and the structural basis for the high neutralization potency of dIgA in an epitope-specific manner.
Year:
2025
A key mechanism of antiviral antibodies is to bind cell-surface viral antigens and activate cellular immunity to clear infected cells, yet antibodies targeting human cytomegalovirus (HCMV) have exhibited limited efficacy. This appears due to HCMV’s multiple immune evasion mechanisms, including viral receptors (vFcγRs) which bind human IgG Fc domains to co-operatively inhibit Fc activation of host Fcγ receptors and impair Fc-mediated effector functions. We biochemically characterized and evaluated the functions of two highly conserved vFcγRs, gp34 and gp68, and mapped their binding epitopes on the Fc domain. Based on this information, we then engineered Fc variants that retain binding to CD16A, which is essential for NK activation, and to FcRn but have markedly attenuated binding to gp34 and gp68. IgG1 antibodies targeting the gB fusogen with engineered Fc domains were not internalized by infected cells, mediated enhanced CD16A activation and limited viral spread in HCMV-infected fibroblasts more effectively than wild-type Fc. Together, this work demonstrates a strategy to enhance the efficacy of antibody therapies to clear HCMV infections. Highlights Host and HCMV FcR compete for IgG1 binding but engage different residues. Fc-engineering abrogates viral FcR antagonism while retaining CD16A activation. Antibodies that resist vFcR capture promote superior ADCC against infected cells. Designer Fc domains complement Fabs to create enhanced disease-specific therapies.
Year:
2025
Supplementary Figure S5. (A) Representative dotplots showing the levels of trogocytosis and killing activity mediated by TAM co-cultured with cetuximab-opsonized PKH67+A431 cells at a 50:1 E:T ratio for 12 hrs in the presence of blocking anti-CD32a Ab (clone 2B6) or blocking anti-CD32a Ab (clone 6G11). (B and C) Summary results showing the levels of trogocytosis (B) and killing activity (C) mediated by blood monocytes and TAM co-cultured with cetuximab-opsonized PKH67+A431 cells at a 50:1 E:T ratio for 12 hrs in the presence of blocking anti-CD32a Ab (clone2B6) or anti-CD32a Ab (clone 6G11). Blocking anti-CD32a Ab were added at concentration (10ug/ml). Summary graphs represent the total tumoricidal activity of effectors that was calculated as described in material and methods. IC Ab-isotype control Abs. (D) Representative experiment and cumulative results showing the kinetics of GFP+A431 tumor cell growth with blood monocytes or TAM at a 50:1 E:T ratio in the presence of cetuximab and blocking anti-CD32a Ab (clone2B6) or blocking anti-CD32a Ab (clone 6G11) in the IncuCyte® Live Cell Analysis System. Percentage of tumor cell growth inhibition/stimulation was calculated at 60 hrs as described earlier. Number of patients included in each analysis is indicated on the graphs. One-way ANOVA with Friedman multiple comparisons test. All data represented as mean ± SEM.
Year:
2024
Supplementary Table S2. Heatmap showing comparisons of the abilities of different types of blood and tumor FcR+ effectors to affect tumor cell growth depending on targeted tAg density, E:T ratios, and anti-tumor Ab isotypes. The indicated FcR+ effectors were added to EGFRhiA431 (high tAg density) or EGFRloA549 (low tAg density) tumor cells at different E:T ratios in the presence of cetuximab (IgG) or IgA anti-EGFR Ab (IgA). The effect on the tumor cell growth was determined at 48 hours using the IncuCyte Live Cell Analysis System. The numbers on the heatmap represent the percent of inhibition of tumor growth. A positive value indicates the inhibition of tumor growth (degrees of red color). A negative value indicates the stimulation of tumor cell growth (degrees of green color). The numbers represent the mean values obtained from experiments shown in Fig.1I, 1K, 4I, and 4J.
Year:
2024
Supplementary Figure S3. The correlation analyses between the ability of blood and tumor FcR+ myeloid effectors to regulate A431 tumor cell growth in the presence of anti-EGFR Abs and the expression of indicated FcR on the surface of these effectors. The effect of FcR+ effectors on A431 tumor cell growth was evaluated in IncuCyte® Live Cell Analysis System. The expression of FcR was analyzed in a single-cell suspension obtained from digested tumors by flow cytometry. Spearman test. Number of patients included in each analysis is indicated on the graphs
Year:
2024
Supplementary Figure S1. (A and B) Flow cytometric analysis of indicated markers of NK and DC in the single cell suspension obtained from digested lung tumor. (C) The comparison among the frequencies of tumor FcR+ effectors and lung tumor stages; All data represented as mean ± SEM. One-way ANOVA with Turkey’s multiple comparisons test. (D) Cumulative flow cytometry results showing the ability of blood and tumor FcR+ effectors to kill PKH-67+A431 tumor cells in the presence of nonspecific human IgG1 isotype control Abs (1ug/ml) at a 50:1 E:T ratio in a 12 hrs FACS-based assay. (E) Cumulative results showing the kinetics of GFP+A431 tumor cell growth when co-cultured with blood and tumor FcR+ effectors for 48 hrs at 50:1 E:T ratio in the presence of IgG1 isotype control Abs in the IncuCyte® Live Cell Analysis System. One-way ANOVA with Dunnett’s multiple comparisons test. (F) Cumulative results showing the kinetics of GFP+A431 tumor cell growth co-cultured with PBN isolated from lung cancer patients and healthy volunteers for 48 hrs at a 50:1 E:T ratio in the presence of human IgG1 isotype control Abs in the IncuCyte® Live Cell Analysis System.
Year:
2024
The clinical benefits of tumor-targeting antibodies (tAb) are modest in solid human tumors. The efficacy of many tAbs is dependent on Fc receptor (FcR)–expressing leukocytes that bind Fc fragments of tAb. Tumor-associated macrophages (TAM) and neutrophils (TAN) represent the majority of FcR + effectors in solid tumors. A better understanding of the mechanisms by which TAMs and TANs regulate tAb response could help improve the efficacy of cancer treatments. Here, we found that myeloid effectors interacting with tAb-opsonized lung cancer cells used antibody-dependent trogocytosis (ADT) but not antibody-dependent phagocytosis. During this process, myeloid cells “nibbled off” tumor cell fragments containing tAb/targeted antigen (tAg) complexes. ADT was only tumoricidal when the tumor cells expressed high levels of tAg and the effectors were present at high effector-to-tumor ratios. If either of these conditions were not met, which is typical for solid tumors, ADT was sublethal. Sublethal ADT, mainly mediated by CD32 hi CD64 hi TAM, led to two outcomes: (i) removal of surface tAg/tAb complexes from the tumor that facilitated tumor cell escape from the tumoricidal effects of tAb; and (ii) acquisition of bystander tAgs by TAM with subsequent cross-presentation and stimulation of tumor-specific T-cell responses. CD89 hi CD32 lo CD64 lo peripheral blood neutrophils (PBN) and TAN stimulated tumor cell growth in the presence of the IgG1 anti-EGFR Ab cetuximab; however, IgA anti-EGFR Abs triggered the tumoricidal activity of PBN and negated the stimulatory effect of TAN. Overall, this study provides insights into the mechanisms by which myeloid effectors mediate tumor cell killing or resistance during tAb therapy. Significance: The elucidation of the conditions and mechanisms by which human FcR + myeloid effectors mediate cancer cell resistance and killing during antibody treatment could help develop improved strategies for treating solid tumors.
Year:
2024
The clinical benefits of tumor-targeting antibodies (tAb) are modest in solid human tumors. The efficacy of many tAbs is dependent on Fc receptor (FcR)–expressing leukocytes that bind Fc fragments of tAb. Tumor-associated macrophages (TAM) and neutrophils (TAN) represent the majority of FcR + effectors in solid tumors. A better understanding of the mechanisms by which TAMs and TANs regulate tAb response could help improve the efficacy of cancer treatments. Here, we found that myeloid effectors interacting with tAb-opsonized lung cancer cells used antibody-dependent trogocytosis (ADT) but not antibody-dependent phagocytosis. During this process, myeloid cells “nibbled off” tumor cell fragments containing tAb/targeted antigen (tAg) complexes. ADT was only tumoricidal when the tumor cells expressed high levels of tAg and the effectors were present at high effector-to-tumor ratios. If either of these conditions were not met, which is typical for solid tumors, ADT was sublethal. Sublethal ADT, mainly mediated by CD32 hi CD64 hi TAM, led to two outcomes: (i) removal of surface tAg/tAb complexes from the tumor that facilitated tumor cell escape from the tumoricidal effects of tAb; and (ii) acquisition of bystander tAgs by TAM with subsequent cross-presentation and stimulation of tumor-specific T-cell responses. CD89 hi CD32 lo CD64 lo peripheral blood neutrophils (PBN) and TAN stimulated tumor cell growth in the presence of the IgG1 anti-EGFR Ab cetuximab; however, IgA anti-EGFR Abs triggered the tumoricidal activity of PBN and negated the stimulatory effect of TAN. Overall, this study provides insights into the mechanisms by which myeloid effectors mediate tumor cell killing or resistance during tAb therapy. Significance: The elucidation of the conditions and mechanisms by which human FcR + myeloid effectors mediate cancer cell resistance and killing during antibody treatment could help develop improved strategies for treating solid tumors.
Year:
2024
Supplementary Movie S1. TAM-mediated phagocytosis of rituximab-opsonized Daudi tumor cells. PKH26-labeled TAM (red) were incubated with PKH67-labeled Daudi tumor cells (green) at a 3:1 E:T ratio for 2 hrs in the presence of rituximab (1ug/ml). Time-lapse microscopy was performed using a Leica DMI4000 inverted microscope. The images were taken every 5 min with Hamamatsu ImagEM 16-bit cooled EMCCD camera at 20x magnification. Supplementary Movie S2. TAM-mediated trogocytosis of cetuximab-opsonized A431 tumor cells. PKH26-labeled TAM (red) were incubated with PKH67-labeled A431 tumor cells (green) at a 3:1 E:T ratio for 2 hrs in the presence of cetuximab (1ug/ml). Time-lapse microscopy was performed using a Leica DMI4000 inverted microscope. The images were taken every 5 min with Hamamatsu ImagEM 16-bit cooled EMCCD camera at 20x magnification. Supplementary Movie S3. Sublethal trogocytosis performed by PBN during their interaction with cetuximab–opsonized A431 tumor cells. PKH26-labeled PBN (red) were incubated with PKH67-labeled A431 targets (green) at a 10:1 E:T ratio for 2 hrs in the presence of cetuximab (1ug/ml). Time-lapse microscopy was performed using a Leica DMI4000 inverted microscope. The images were taken every 5 min with Hamamatsu ImagEM 16-bit cooled EMCCD camera at 20x magnification. Supplementary Movie S4. Lethal trogocytosis performed by blood monocytes during their interaction with cetuximab–opsonized A431 tumor cells. PKH26-labeled monocytes (red) were incubated with PKH67-labeled A431 targets (green) at a 10:1 E:T ratio for 2 hrs in the presence of cetuximab (1ug/ml). Time-lapse microscopy was performed using a Leica DMI4000 inverted microscope. The images were taken every 5 min with Hamamatsu ImagEM 16-bit cooled EMCCD camera at 20x magnification.
Year:
2024
Supplementary Figure S9. (A and B) Representative dotplots and summary results showing the ability of TAM pretreated with blocking anti-CD64 F(ab')2 and anti-CD32 F(ab')2 fragments (5ug/ml) to kill PKH67+ A431 cells at a 1:1 E:T ratio in the presence of cetuximab (1ug/ml) in a 12 hrs FACS-based assay. Dead A431 tumor cells were defined as TO-PRO-3+PKH67+ cells. (C and D) Representative dotplots and summary results demonstrating the ability of HLA-A2neg TAM to stimulate of Ly95 cells responses (intracellular IFN-γ) after their preincubation with cetuximab-opsonized A549/HLA-A2+NY-ESO tumor cells at the indicated time points. Kruskal-Wallis multiple comparisons test. Data represented as mean ± SEM. (E) The expression of NY-ESO-1 protein in different batches of transduced A549 tumor cells. The expression of intracellular NY-ESO was evaluated by flow cytometry using NY-ESO-1 mAb (clone D1Q2U) that recognizes endogenous levels of total NY-ESO-1 protein. Non transduced A549 cells were used as a control. (F-H) Representative dotplots and cumulative data showing the ability of HLA-A2+TAM to stimulate of Ly95 cells responses (intracellular IFN-γ) after preincubation with A549/HLA-A2+NY-ESOhi (F) and A549/HLA-A2+NY-ESOlo tumor cells (G) in the presence or absence of cetuximab for 4 hrs. Wilcoxon matched pairs test for groups with (+) or without (-) Ab. * p
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Collaborators (12)
Jiwon Lee
Associate Professor
Korea University
Hartmut Hengel
University of Freiburg
Annalee Nguyen
Research Assistant Professor
University of Texas at Austin
Richard Stanton
Professor of Virology
Cardiff University
Julianna Han
Senior staff scientist
Scripps Research
Jennifer A Maynard
University of Texas at Austin
Sunil Singhal
University of Pennsylvania
Steven Albelda
Professor
University of Pennsylvania
Jason S. McLellan
University of Texas at Austin
Zunlong Ke
Assistant Professor
University of Texas at Austin
Ralph Baric
Professor
University of North Carolina at Chapel Hill
Philipp Kolb
Group leader
University Medical Center Freiburg
Make your next move.
Prepare your application
Review drafts before you send them.